Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Pediatric HIV costs across three treatment eras from 1986 to 2007.

Wilson LS, Basu R, Christenson M, Hensic L, Paoli C, Wara D, Moskowitz JT.

Pediatrics. 2010 Sep;126(3):e541-9. doi: 10.1542/peds.2009-3485. Epub 2010 Aug 9.

PMID:
20696721
2.

Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.

Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D.

J Acquir Immune Defic Syndr. 2001 May 1;27(1):14-9.

PMID:
11404515
4.

Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.

Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P, Hellinger J, Rutstein R, Keiser P, Rubin H, Moore RD; HIV Research Network..

Med Care. 2005 Sep;43(9 Suppl):III40-52.

PMID:
16116308
5.
6.

Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.

Beck EJ, Mandalia S, Griffith R, Beecham J, Walters MD, Boulton M, Miller DL.

Pharmacoeconomics. 2000 Jan;17(1):53-69.

PMID:
10747765
7.

Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.

Torti C, Casari S, Palvarini L, Quiros-Roldan E, Moretti F, Leone L, Patroni A, Castelli F, Ripamonti D, Tramarin A, Carosi G.

Health Policy. 2003 Sep;65(3):261-7.

PMID:
12941493
8.

The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.

Krentz HB, Auld MC, Gill MJ; HIV Economic Study Group..

CMAJ. 2003 Jul 22;169(2):106-10.

9.

Costs of HIV medical care in the era of highly active antiretroviral therapy.

Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD.

AIDS. 1999 May 28;13(8):963-9.

PMID:
10371178
10.

The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.

Hubben GA, Bishai D, Pechlivanoglou P, Cattelan AM, Grisetti R, Facchin C, Compostella FA, Bos JM, Postma MJ, Tramarin A.

AIDS Care. 2008 Apr;20(4):449-55. doi: 10.1080/09540120701867107.

PMID:
18449822
11.

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.

Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA.

AIDS. 2004 Dec 3;18(18):2411-8.

PMID:
15622317
12.

Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment?

Farnham PG.

Appl Health Econ Health Policy. 2010;8(2):75-88. doi: 10.2165/11531890-000000000-00000.

PMID:
20175587
13.

Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand.

Kitajima T, Kobayashi Y, Chaipah W, Sato H, Chadbunchachai W, Thuennadee R.

AIDS. 2003 Nov 7;17(16):2375-81.

PMID:
14571190
14.

Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).

Rothbard AB, Lee S, Blank MB.

J Ment Health Policy Econ. 2009 Dec;12(4):187-94.

PMID:
20195006
15.

Costing of scaling up HIV/AIDS treatment in Mexico.

Bautista-Arredondo S, Dmytraczenko T, Kombe G, Bertozzi SM.

Salud Publica Mex. 2008;50 Suppl 4:S437-44.

16.

The oncology impact of highly active antiretroviral therapy.

Schlichemeyer R, Chambers C, Gill MJ.

J Oncol Pharm Pract. 2007 Mar;13(1):17-25.

PMID:
17621563
17.
18.

The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.

Marseille E, Saba J, Muyingo S, Kahn JG.

AIDS. 2006 Apr 4;20(6):907-14.

PMID:
16549976
19.

Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.

Ghatnekar O, Hjortsberg C, Gisslén M, Lindbäck S, Löthgren M.

Pharmacoeconomics. 2010;28 Suppl 1:49-57. doi: 10.2165/11587440-000000000-00000.

PMID:
21182343
20.

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.

Corzillius M, Mühlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U.

Antivir Ther. 2004 Feb;9(1):27-36.

PMID:
15040534

Supplemental Content

Support Center